Arthritis gene therapy's first death

In July 2007 a subject died while enrolled in an arthritis gene therapy trial. The study was placed on clinical hold while the circumstances surrounding this tragedy were investigated. Early in December 2007 the Food and Drug Administration removed the clinical hold, allowing the study to resume wit...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Christopher H, Ghivizzani, Steven C, Robbins, Paul D
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2008
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483436/
https://www.ncbi.nlm.nih.gov/pubmed/18510784
http://dx.doi.org/10.1186/ar2411
_version_ 1782158028746784768
author Evans, Christopher H
Ghivizzani, Steven C
Robbins, Paul D
author_facet Evans, Christopher H
Ghivizzani, Steven C
Robbins, Paul D
author_sort Evans, Christopher H
collection PubMed
description In July 2007 a subject died while enrolled in an arthritis gene therapy trial. The study was placed on clinical hold while the circumstances surrounding this tragedy were investigated. Early in December 2007 the Food and Drug Administration removed the clinical hold, allowing the study to resume with minor changes to the protocol. In the present article we collate the information we were able to obtain about this clinical trial and discuss it in the wider context of arthritis gene therapy.
format Text
id pubmed-2483436
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-24834362008-07-25 Arthritis gene therapy's first death Evans, Christopher H Ghivizzani, Steven C Robbins, Paul D Arthritis Res Ther Commentary In July 2007 a subject died while enrolled in an arthritis gene therapy trial. The study was placed on clinical hold while the circumstances surrounding this tragedy were investigated. Early in December 2007 the Food and Drug Administration removed the clinical hold, allowing the study to resume with minor changes to the protocol. In the present article we collate the information we were able to obtain about this clinical trial and discuss it in the wider context of arthritis gene therapy. BioMed Central 2008 2008-05-27 /pmc/articles/PMC2483436/ /pubmed/18510784 http://dx.doi.org/10.1186/ar2411 Text en Copyright © 2008 BioMed Central Ltd
spellingShingle Commentary
Evans, Christopher H
Ghivizzani, Steven C
Robbins, Paul D
Arthritis gene therapy's first death
title Arthritis gene therapy's first death
title_full Arthritis gene therapy's first death
title_fullStr Arthritis gene therapy's first death
title_full_unstemmed Arthritis gene therapy's first death
title_short Arthritis gene therapy's first death
title_sort arthritis gene therapy's first death
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2483436/
https://www.ncbi.nlm.nih.gov/pubmed/18510784
http://dx.doi.org/10.1186/ar2411
work_keys_str_mv AT evanschristopherh arthritisgenetherapysfirstdeath
AT ghivizzanistevenc arthritisgenetherapysfirstdeath
AT robbinspauld arthritisgenetherapysfirstdeath

Ejemplares similares